{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(10)"],"submitter":["Gondoputro W"],"pubmed_abstract":["<h4>Background</h4>In active surveillance there is significant interest in whether imaging modalities such as multiparametric magnetic resonance imaging (mpMRI) or <sup>68</sup>Gallium prostate-specific membrane antigen positron emission tomography/computerized tomography (<sup>68</sup>Ga-PSMA-PET/CT) can improve the detection of progression to clinically significant prostate cancer (csPCa) and thus reduce the frequency of prostate biopsies and associated morbidity. Recent studies have demonstrated the value of mpMRI in active surveillance; however, mpMRI does miss a proportion of disease progression and thus alone cannot replace biopsy. To date, prostate-specific membrane antigen positron emission tomography (PSMA-PET) has shown additive value to mpMRI in its ability to detect prostate ca"],"journal":["Translational andrology and urology"],"pagination":["1598-1606"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10643393"],"repository":["biostudies-literature"],"pubmed_title":["<sup>68</sup>Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study."],"pmcid":["PMC10643393"],"pubmed_authors":["Agrawal S","Gondoputro W","Stricker PD","Frydenberg M","Savdie R","Thompson J","Katelaris A","Scheltema MJ","Wong D","Liu Z","Emmett L","Yaxley J","Roberts MJ","Rasiah K","Malouf D","Shnier R","Doan P","Geboers B","Delprado W"],"additional_accession":[]},"is_claimable":false,"name":"<sup>68</sup>Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study.","description":"<h4>Background</h4>In active surveillance there is significant interest in whether imaging modalities such as multiparametric magnetic resonance imaging (mpMRI) or <sup>68</sup>Gallium prostate-specific membrane antigen positron emission tomography/computerized tomography (<sup>68</sup>Ga-PSMA-PET/CT) can improve the detection of progression to clinically significant prostate cancer (csPCa) and thus reduce the frequency of prostate biopsies and associated morbidity. Recent studies have demonstrated the value of mpMRI in active surveillance; however, mpMRI does miss a proportion of disease progression and thus alone cannot replace biopsy. To date, prostate-specific membrane antigen positron emission tomography (PSMA-PET) has shown additive value to mpMRI in its ability to detect prostate ca","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2026-07-14T19:22:33.56Z","creation":"2024-11-14T05:56:53.686Z"},"accession":"S-EPMC10643393","cross_references":{"pubmed":["37969779"],"doi":["10.21037/tau-22-708"]}}